Gw Pharmaceuticals Plc Quick Ratio (GWPH) starting from the first quarter 2021 to first quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Gw Pharmaceuticals Plc  (NASDAQ: GWPH)

Gw Pharmaceuticals Plc's Quick Ratio

GWPH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2021, Quick Ratio fell to 2.86 a new company low.

Within Major Pharmaceutical Preparations industry 425 other companies have achieved higher Quick Ratio than Gw Pharmaceuticals Plc in first quarter 2021. While Quick Ratio total ranking in the first quarter 2021 has deteriorated compared to the prior quarter from 1040 to 1696.

Explain Quick Ratio?
How much Cash & cash equivalents GWPH´s has?
What are GWPH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GWPH Quick Ratio (Mar 31 2021)
Q1		 (Dec 31 2020)
Q4		 (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1
Y / Y Current Liabilities Change 54.87 % 35.93 % 47.26 % 41.16 % 32.73 %
Y / Y Cash & cash equivalent Change -8.55 % -9.35 % -13.4 % -18.18 % -3.97 %
Quick Ratio MRQ 2.86 3.05 3.42 4.03 4.84
GWPH's Total Ranking # 1696 # 1040 # 1195 # 779 # 563
Seq. Current Liabilities Change 0.28 % 13.91 % 18.38 % 14.53 % -11.98 %
Seq. Cash & cash equivalent Change -5.89 % 1.34 % 0.58 % -4.67 % -6.7 %



Quick Ratio first quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 426
Healthcare Sector # 723
Overall Market # 1696


Quick Ratio Statistics
High Average Low
8.99 5.4 2.86
(Dec 31 2018)   (Mar 31 2021)




Financial Statements
Gw Pharmaceuticals Plc's Current Liabilities $ 160 Millions Visit GWPH's Balance sheet
Gw Pharmaceuticals Plc's Cash & cash equivalent $ 458 Millions Visit GWPH's Balance sheet
Source of GWPH's Sales Visit GWPH's Sales by Geography


Cumulative Gw Pharmaceuticals Plc's Quick Ratio

GWPH's Quick Ratio for the trailling 12 Months

GWPH Quick Ratio

 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months		 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months
Y / Y Current Liabilities TTM Growth 44.62 % 39.32 % 48.58 % 51.61 % 63.11 %
Y / Y Cash & cash equivalent TTM Growth -12.57 % -11.44 % -11.36 % 0.89 % 21.56 %
Quick Ratio TTM 3.29 3.73 4.16 4.76 5.44
Total Ranking TTM # 4713 # 894 # 4660 # 4636 # 4597
Seq. Current Liabilities TTM Growth 10.87 % 8.8 % 10.35 % 8.63 % 6.81 %
Seq. Cash & cash equivalent TTM Growth -2.2 % -2.51 % -3.59 % -4.88 % -0.94 %

Quick ratio ranking by company, industry and sector >> Back to GWPH Financial Strength Comparisons >> Go to Compare GWPH Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q1 2021 to $160.25 millions, cumulative Quick Ratio decreased to 3.29 below the Gw Pharmaceuticals Plc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 498 other companies have achieved higher Quick Ratio than Gw Pharmaceuticals Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2020 from 894 to 4713.

Explain Quick Ratio?
How much Cash & cash equivalents GWPH´s has?
What are GWPH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 499
Healthcare Sector # 980
Within the Market # 4713


trailing twelve months Quick Ratio Statistics
High Average Low
7.15 5.17 3.29
(Jun 30 2019)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Mar 31 2021, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2021 MRQ Cash & cash equivalentMar 31 2021 MRQ Current Liabilities
Eton Pharmaceuticals Inc   7.85 $ 25.113  Millions$ 3.199  Millions
Opiant Pharmaceuticals Inc   7.81 $ 48.048  Millions$ 6.149  Millions
Provention Bio Inc   7.75 $ 207.205  Millions$ 26.752  Millions
Portage Biotech Inc   7.70 $ 28.373  Millions$ 3.685  Millions
Elicio Therapeutics Inc   7.69 $ 130.456  Millions$ 16.963  Millions
Epizyme Inc.  7.66 $ 298.943  Millions$ 39.006  Millions
Marinus Pharmaceuticals Inc   7.66 $ 123.472  Millions$ 16.121  Millions
Trevena inc   7.64 $ 97.720  Millions$ 12.788  Millions
Gt Biopharma Inc   7.60 $ 27.555  Millions$ 3.626  Millions
Axsome Therapeutics Inc   7.59 $ 164.660  Millions$ 21.683  Millions
Blueprint Medicines Corporation  7.58 $ 851.961  Millions$ 112.437  Millions
Travere Therapeutics Inc   7.57 $ 520.871  Millions$ 68.813  Millions
Gyre Therapeutics Inc   7.55 $ 107.000  Millions$ 14.181  Millions
Applied Therapeutics Inc   7.49 $ 148.059  Millions$ 19.774  Millions
Strongbridge Biopharma plc  7.46 $ 73.898  Millions$ 9.901  Millions
Calithera Biosciences Inc   7.46 $ 102.851  Millions$ 13.792  Millions
Zogenix Inc   7.44 $ 435.222  Millions$ 58.531  Millions
Calliditas Therapeutics Ab  7.43 $ 211.166  Millions$ 28.413  Millions
Neubase Therapeutics inc   7.41 $ 24.500  Millions$ 3.306  Millions
Zynerba Pharmaceuticals Inc   7.41 $ 93.130  Millions$ 12.568  Millions
Geron Corporation  7.40 $ 211.390  Millions$ 28.552  Millions
Medicenna Therapeutics Corp.  7.40 $ 24.163  Millions$ 3.267  Millions
Merus N v   7.32 $ 387.496  Millions$ 52.955  Millions
Royalty Pharma Plc  7.22 $ 1,846.984  Millions$ 255.983  Millions
Novabridge Biosciences  7.21 $ 671.123  Millions$ 93.107  Millions
Avadel Pharmaceuticals Plc  7.19 $ 62.097  Millions$ 8.636  Millions
Xeris Biopharma Holdings Inc   7.12 $ 135.894  Millions$ 19.086  Millions
Immunic Inc   7.02 $ 114.839  Millions$ 16.356  Millions
Can fite Biopharma Ltd   6.97 $ 19.139  Millions$ 2.745  Millions
Aprea Therapeutics Inc   6.92 $ 77.616  Millions$ 11.215  Millions

Date modified: 2026-09-26T07:35:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.